Acadia expects Rett drug protection through 2041
Acadia Pharmaceuticals received a U.S. patent allowance covering weight-banded dosing of trofinetide, the active ingredient in DAYBUE and DAYBUE STIX for Rett syndrome. Including pediatric exclusivity, the patent is expected to extend U.S. protection to March 28, 2041—nearly five years beyond existing method-of-use protection.
Health · 7 sources · 3hRead itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Rett syndrome
Rett syndrome (RTT) is a genetic disorder that typically becomes apparent after 6–18 months of age and almost exclusively in girls. Symptoms include impairments in language and coordination, and repetitive movements. Those affected often have slower growth, difficulty walking, and a smaller head size. Complications of Rett syndrome can include seizures, scoliosis, and sleeping problems. The severity of the condition is variable.
Everything about Rett syndrome →